U.S. Household Products Stock News

Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier. See our latest analysis for Legend Biotech. Legend Biotech’s latest earnings and leadership change in July have come against a mixed share price backdrop, with a 1-year total shareholder return that declined 38.5% and a 3-year total shareholder return that declined 68.3%. Meanwhile, the year-to-date...

Kilroy Realty (KRC) is back in focus after the company announced the departure of Chief Financial Officer and Executive Vice President Jeffrey Kuehling on August 11, 2026, and appointed Eliott Trencher as interim principal financial officer. See our latest analysis for Kilroy Realty. The executive change follows a mixed period for Kilroy Realty’s stock, with a 30 day share price return down 10.16% and a 3 year total shareholder return of 27.11%, indicating that longer term holders have...

In August 2026, Mineralys Therapeutics reported a second-quarter net loss of US$241.07 million and a six-month net loss of US$280.41 million, while also appointing veteran cardiologist and drug developer James J. “Terry” Ferguson III, M.D., as its new Chief Medical Officer with his predecessor moving into a full-time advisory role. These developments came as the company advanced its lead therapy lorundrostat toward an expected FDA decision and bolstered its balance sheet with US$150 million...

Watsco (WSO) continues to attract attention after recent share price moves, with the stock closing at US$313.65. Investors are weighing this level against its value score of 4 and broader return history. See our latest analysis for Watsco. Recent trading has been choppy for Watsco, with a 1-day share price return of 0.57%, a 30-day share price return that is down 15.67%, and a 1-year total shareholder return that is down 23.74%. This points to fading momentum despite a positive 5-year total...

The Morning Bull - US Market Morning Update Wednesday, Aug, 19 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.5% and Nasdaq-100 futures weaker by more than 1%. The main drag is a global bond selloff, as the US 10 year yield moves near 4.7% and France and Germany see their own 10 year borrowing costs reach multi year highs. Higher yields mean governments and companies face steeper interest bills, which can pressure stock valuations. At the...

Installed Building Products, Inc. recently reported second-quarter 2026 results showing sales of US$777.8 million and net income of US$64.9 million, while also completing a US$101.95 million share repurchase program and declaring a US$0.39 per-share cash dividend for both the second and third quarters of 2026. The combination of lower year-over-year earnings, active buybacks, and an increased third-quarter dividend raises questions about how management is balancing growth investment with...

SM Energy (SM) has been in focus after its stock moved in step with a jump in crude prices, as investors reacted to rising geopolitical risk linked to Iran and concerns about potential supply disruptions. See our latest analysis for SM Energy. Those geopolitical shocks have come on top of a busy few weeks for SM Energy, which has reported higher second quarter revenue and net income, updated its 2026 production guidance, continued buying back shares, and prepared to redeem US$417 million of...

International Paper (IP) has drawn renewed attention after recent share price moves, with the stock down about 4% over the past week but up roughly 7% over the past month. See our latest analysis for International Paper. Zooming out, International Paper’s share price has climbed 29.7% over the past 90 days but the 1 year total shareholder return is down 11.2%. This suggests recent momentum follows a weaker longer term experience for investors. If this kind of swing in sentiment has you...

Definium Therapeutics (DFTX) reported positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder, with the study meeting its primary and key secondary efficacy endpoints and showing a favorable safety profile. See our latest analysis for Definium Therapeutics. Definium Therapeutics shares have rallied strongly into these Voyage results, with a 7 day share price return of 12.88% and a 90 day share price return of 121.27%. The 1 year total shareholder return of...

Crescent Energy dividend decision and why it matters Crescent Energy (CRGY) recently declared a total dividend of $0.12 per share, with an ex-dividend date of 17 August 2026. The consistent quarterly payouts since 2022 now sit alongside weaker dividend growth and earnings trends. See our latest analysis for Crescent Energy. Crescent Energy’s recent dividend news comes alongside strong share price momentum in 2026, with a 1-month share price return of 20.47% and a year to date share price...

Horizon Bancorp (HBNC) recently expanded its Board of Directors from 11 to 13 members, adding Nicholas J. Ritter and Charles W. Sulerzyski to the Class of 2027 and to the Horizon Bank board. See our latest analysis for Horizon Bancorp. At a share price of $20.28, Horizon Bancorp has seen modest short term share price softness, while its 90 day share price return of 10.64% and 1 year total shareholder return of 31.20% point to stronger underlying momentum. If this board refresh has you...

Right now, tariffs and trade rules are reshaping the economics of polysilicon and solar grade silicon, turning supply chains into a live stress test for listed stocks. That disruption can create pricing power for some companies and fresh risks for others, which is why investors are watching this corner of the market so closely. This article walks through three screened stocks that appear particularly exposed to the latest policy shock. The three stocks highlighted below are just a starting...

BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month. See our latest analysis for BeOne Medicines. Following the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return...

La-Z-Boy (LZB) is back in focus after reporting first quarter results for the period ended July 25, 2026, showing sales of US$475.69 million and a net loss of US$2.29 million. See our latest analysis for La-Z-Boy. The earnings miss and quarterly net loss have taken some heat out of La-Z-Boy’s recent gains, with the share price down 1.7% over the past week but still up 14.9% over 90 days and a 3 year total shareholder return of 46.7%. This suggests longer term holders have seen stronger...

Why Roivant Sciences Earnings Matter For Shareholders Roivant Sciences (ROIV) reported first quarter 2026 results with sales of US$1.44 million compared to US$2.17 million a year earlier, while the net loss narrowed to US$189.84 million from US$223.36 million. See our latest analysis for Roivant Sciences. Roivant Sciences shares have gained momentum around the earnings release, with a 1-month share price return of 8.29% and a year to date share price return of 70.41%. The 1-year total...

CNB Financial (CCNE) drew fresh attention after its Board declared a quarterly cash dividend of $0.19 per share, payable on September 15, 2026, to shareholders of record on September 1, 2026. See our latest analysis for CNB Financial. At a share price of US$34.82, CNB Financial has seen its short term momentum build, with a 90 day share price return of 14.09% and a year to date share price return of 35.28%. The 1 year total shareholder return of 43.63% and 3 year total shareholder return of...

Why Trulieve Cannabis Stock Is Back In Focus After Its NYSE Debut Trulieve Cannabis (TRLV) drew fresh attention after ringing the New York Stock Exchange Closing Bell and becoming the first U.S. cannabis company to list on the NYSE. The move signals higher visibility and potentially wider investor access. The NYSE listing sits alongside Trulieve Cannabis operations that include 207 medical dispensaries, 5,000 employees, and 3.5 million square feet of cultivation and production capacity across...

In August 2026, Amylyx Pharmaceuticals reported positive topline Phase 3 LUCIDITY results showing avexitide significantly reduced serious hypoglycemic events in post-bariatric hypoglycemia after Roux-en-Y gastric bypass, while also launching a US$350,000,000 follow-on common stock offering and outlining plans to submit a New Drug Application by late 2026. This marks progress for a first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies, potentially opening a...

Sea stock is coming off a sharp three year gain of 218.3% but the valuation signals are split, with the Discounted Cash Flow (DCF) intrinsic value pointing to upside while market based multiples lean the other way. That mix leaves investors weighing a strong share price recovery against a set of checks that only partly support the current level. Sea has returned 218.3% over the last three years, which puts the focus on whether that rebound already reflects most of the good news. The recent...

Why MannKind's latest earnings matter for shareholders MannKind (MNKD) recently reported second quarter 2026 results that combined higher revenue with a shift back to losses. This mix of topline expansion and weaker profitability is now central to how investors assess the stock. See our latest analysis for MannKind. MannKind's recent earnings release has arrived after a period where the stock has swung between pressure and recovery, with a 25.23% 90 day share price return against a weaker...

Shelf registration puts funding options on the table National Fuel Gas (NFG) has filed an omnibus shelf registration covering debt, common and preferred stock, depositary shares, stock purchase contracts and units. This filing refreshes the company’s ability to raise capital through multiple security types. See our latest analysis for National Fuel Gas. At a share price of US$83.37, National Fuel Gas has seen a 1-day share price return of 1.89% and a 30-day share price return of 3.00%. The...

Tango Therapeutics, Inc. recently reported a wider net loss of US$55.34 million for the second quarter of 2026, filed a US$400 million at-the-market follow-on equity offering, and made several leadership changes including appointing a new Chairman and a future Chief Commercialization Officer. These moves point to a company aligning its capital-raising plans with the build-out of commercialization expertise as it prepares vopimetostat for later-stage development. Next, we will examine how the...

What Viridian Therapeutics’ Latest Earnings Mean For Investors Viridian Therapeutics (VRDN) reported its second quarter and six month results to June 30, 2026, giving investors fresh detail on revenue and losses that appear to be driving recent stock interest. Quarterly revenue was US$0.284 million compared with US$0.075 million a year earlier. Net loss for the period was US$127.12 million, with basic loss per share from continuing operations at US$1.05 compared with US$1 in the prior year...

In August 2026, MDU Resources Group’s board raised its quarterly dividend to US$0.145 per share, updated its long‑term dividend payout ratio target to 55%–65% of earnings, and set an October 1, 2026 payment date for shareholders of record on September 10, 2026. This combination of a higher cash payout and a lower target payout range highlights management’s focus on balancing income returns with earnings retention for future investment. Next, we’ll examine how the dividend increase and...